 And fourth, using data analytics to keep pace with constantly evolving fraud schemes. The DOJ also alleges corporate executives committed a $90 million fraud scheme by distributing adulterated and wrongfully branded HIV medication, more than $146 million in fake addiction treatment schemes, more than $1.1 billion in telemedicine and laboratory fraud, as well as $450 million in other health care fraud and opioid schemes.